THNR — Amplify Weight Loss Drug & Treatment ETF
Data updated: 2026-05-27
THNR — Amplify Weight Loss Drug & Treatment ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. Global (incl. US) Materials Equity · $4.15M AUM · 0.59% expense ratio · 15.4% 1-yr return. From SEC regulatory filings.
THNR Fund Overview
THNR — Amplify Weight Loss Drug & Treatment ETF is a US mutual fund managed by Amplify ETF Trust, categorised as Global (incl. US) Materials Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Amplify ETF Trust
- Category: Global (incl. US) Materials Equity
- Assets under management: $4.15M
- 1-year return: 15.4%
- Ticker: THNR
- SEC CIK: 0001633061
- SEC series ID: S000085024
- Share class ID: C000249887
THNR Holdings
Top 10 holdings of Amplify Weight Loss Drug & Treatment ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Novo Nordisk A/S | 11.89% |
| Eli Lilly & Co | 11.56% |
| Regeneron Pharmaceuticals Inc | 6.77% |
| Amgen Inc | 6.27% |
| Chugai Pharmaceutical Co Ltd | 6.00% |
| CSPC Pharmaceutical Group Ltd | 5.03% |
| Arrowhead Pharmaceuticals Inc | 4.96% |
| AbbVie Inc | 4.75% |
| AstraZeneca PLC | 4.66% |
| Pfizer Inc | 4.62% |
THNR Portfolio Allocation
Asset-class allocation of Amplify Weight Loss Drug & Treatment ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 95.2% |
| Cash & Equivalents | 3.0% |
THNR Performance
Total returns for THNR (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -3.0% |
| 1 year | 15.4% |
| 3 years (annualised) | -0.3% |
THNR Risk Information
Risk metrics for THNR, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 14.3%
THNR Costs and Fees
THNR costs about $59 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.59%
- Gross expense ratio: 0.59%
- Portfolio turnover: 70%
- Brokerage commissions: 2.60 bps of average net assets (SEC N-CEN)
THNR Cashflows
Over the 12 months to 2026-03, Amplify Weight Loss Drug & Treatment ETF had net outflows of $57.59K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | $0 |
| 2026-02 | $519.34K |
| 2026-01 | $1.03M |
| 2025-12 | $0 |
| 2025-11 | $0 |
| 2025-10 | −$492.53K |
THNR Debt Constituents
No individual debt constituents are reported in Amplify Weight Loss Drug & Treatment ETF's latest SEC N-PORT filing.
THNR Prospectus and SEC Filings
Official Amplify Weight Loss Drug & Treatment ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other Global (incl. US) Materials Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.